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Oxandrolone Treatment in Adults with
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Severe thermal injury is associated with hypermetabolism and hyper-
catabolism, leading to skeletal muscle breakdown, lean body mass loss, weight
loss, and negative nitrogen balance. Muscle protein catabolism in patients
with severe thermal injury is the result of stress-induced increased release of
cytokines and counterregulatory hormones. Coupled with decreased serum
anabolic hormone concentrations such as testosterone and growth hormone
along with the presence of insulin resistance, anabolism in patients with
severe thermal injury is inefficient or impossible during the acute postburn
period. This causes difficulty in restoring lean body mass and regaining lost
body weight, as well as poor healing of the burn wound and delayed patient
recovery. Oxandrolone, a synthetic derivative of testosterone, has been used in
adult patients with severe thermal injury to enhance lean body mass
accretion, restore body weight, and accelerate wound healing. In clinical
studies, oxandrolone 10 mg orally twice/day improved wound healing,
restored lean body mass, and accelerated body weight gain. During the
rehabilitation period, oxandrolone therapy with adequate nutrition and
exercise improved lean body mass, increased muscle strength, and restored
body weight. However, most data on oxandrolone use in adult patients with
severe thermal injury are derived from single-center studies, many of which
enrolled a relatively small number of subjects and some of which had a poor
design. Multicenter, prospective, randomized studies are needed to better
define the optimal oxandrolone dosage and to confirm the efficacy and safety
of this drug in adult patients with severe thermal injury.
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Conclusion
Severe thermal injury is associated with
metabolic and hormonal changes that correlate
with the extent and severity of injury. During the
period immediately after the severe thermal
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injury, hypermetabolism and hypercatabolism
result in skeletal muscle breakdown and loss of
lean body mass. Anabolic agents including
recombinant human growth hormone, recombi-
nant human insulin growth factor-1 (IGF-1),
insulin, testosterone, and oxandrolone have been
used to enhance lean body mass accretion,
promote wound healing, and restore body weight
of patients with severe thermal injury.1
Metabolic Changes
The metabolic response to severe thermal
injury is biphasic. The early “ebb” phase occurs
immediately after the injury and is characterized
by hypovolemia, tissue hypoxia, and decreased
cardiac output, oxygen consumption, body
temperature, and metabolic rate. The subsequent
12–24 hours is the “flow” phase, which is
characterized by increased cardiac output and
oxygen consumption, hypermetabolism, and
hypercatabolism.2 During the flow phase,
increased release of counterregulatory hormones
(catecholamines, glucocorticoids, glucagon) and
cytokines (interleukin-1, interleukin-6, tumor
necrosis factor-) cause proteolysis, lipolysis, and
glycogenolysis.3 Patients with total body surface
area (TBSA) burns of 60% or greater are at higher
risk for morbidity and mortality compared with
those with smaller TBSA burns. This may likely
be due to increased hypermetabolic and
inflammatory reactions as well as impaired
cardiac function with larger thermal injuries.
Protein breakdown correlates with the percent
TBSA burn and the patient’s metabolic rate.4
Sepsis and hyperglycemia further aggravate
catabolism. Protein catabolism results in lean
body mass loss and negative nitrogen balance.
Urinary and wound nitrogen losses are signifi-
cantly increased such that protein synthesis is
unable to compensate for nitrogen breakdown.
Amino acid metabolism is also disrupted, with
decreased amino acid influx into cells relative to
increased amino acid efflux.5 Stress-induced
hyperglycemia and insulin resistance are
common in critically ill patients with severe
thermal injury. Uncontrolled hyperglycemia
increases proteolysis by 3-fold and is associated
with higher frequency of graft failure and
infections.3, 6 Lipid metabolism is also altered,
with accelerated lipolysis resulting in free fatty
acid release at a rate that exceeds fatty acid
oxidation, which leads to hypertriglyceridemia.7
Diminished fat utilization limits the lipid protein-
sparing effect whereby muscle proteins become a
preferential source of energy.8 Bone demineral-
ization that is mediated by increased endogenous
corticosteroid and cytokine production also
occurs and may result in skeletal growth delay in
children with severe thermal injury.9
Decreased serum endogenous anabolic
hormone production during severe thermal
injury further delays muscle mass and body
weight gain and wound healing. Significant
weight loss up to approximately 22% of preburn
weight can occur by 8 weeks after severe thermal
injury in patients with more than 40% TBSA
burn.10 Despite adequate nutrition, patients with
severe thermal injury may stay in negative nitrogen
balance for months after the thermal injury.
Nutrition Support
The hypermetabolic response to severe thermal
injury is characterized by a shift in blood supply
to provide energy and nutrients to thermal injury
wounds. Sympathetic hyperactivity causes
tachycardia and increases myocardial contrac-
tility, cardiac workload, oxygen consumption,
and metabolic rate.11 Because metabolic rate
varies among patients with severe thermal injury,
indirect calorimetry using serial resting energy
expenditure (REE) measurements is the most
accurate method to measure energy expenditure,
rather than relying on the less accurate energy
predictive equations. The REE correlates with
thermal injury size, presence of sepsis, ventilator
dependence, and protein catabolism. In pediatric
patients with greater than 40% TBSA burn, REE
reached 180% of the basal metabolic rate during
the acute postburn period, then decreased
incrementally to 150% by the time of full wound
healing around 2 months after the thermal injury,
but remained at 115% at 12 months after thermal
injury.12 Interventions used to decrease the
metabolic rate would reduce energy expenditure.
These include proper sedation, control of pain
and anxiety, maintenance of ambient patient
room temperature at 30–32°C, early wound
grafting and excision, prompt treatment of
infections, supportive psychotherapy, and
propranolol therapy to modulate the hyper-
metabolic response.13 Propranolol is used in
patients with severe thermal injury to block -
adrenergic stimulation to decrease hyper-
metabolism and reduce muscle protein catabolism.14
Providing adequate nutrition to patients with
severe thermal injury is essential to prevent
malnutrition, attempt to achieve anabolism,
maintain adequate immune system, and enhance
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burn wound repair. Wound healing is a complex
process of cellular, molecular, and biochemical
aspects that directly correlates with the nutritional
status. Malnutrition impairs wound healing,
whereas providing adequate nutrition modulates
the wound healing process.15 Nutrition support
should provide daily calories at the level of
measured REE. Increasing caloric intake beyond
1.2 times the REE does not improve lean body
mass, but increases body fat deposition.16
Balancing caloric intake should be guided by
macronutrient utilization and tolerance. Over-
feeding should be avoided because it leads to
serious metabolic complications including
hyperglycemia, hypertriglyceridemia, cholestasis,
hepatic steatosis, and respiratory compromise.17, 18
Adequate protein intake allows lean body mass
building and promotes wound healing. In adult
patients with severe thermal injury whose kidney
and liver functions are normal, amino acids are
provided at 1.5–2 g/kg/day. For optimal glucose
oxidation and metabolism, continuous dextrose
infusion rates should not exceed 4–5 mg/kg/minute
in adult patients receiving parenteral nutrition.17, 19
Enteral feeding is the preferred route of
nutrition support in critically ill patients with
severe thermal injury who have a functional
gastrointestinal tract. Enteral nutrition preserves
intestinal integrity and immunity, and is associated
with less infectious and metabolic complications
compared with parenteral nutrition.20 Parenteral
nutrition is indicated only when enteral nutrition
cannot or should not be used such as in patients
with adynamic ileus or intestinal obstruction.
Using supplemental parenteral nutrition to
enteral feeding has no clinical benefits and may
increase patient mortality.21 Although some
studies report that early (≤ 24 hrs of injury)
enteral nutrition may blunt the hypermetabolic
response of thermal injury, a systematic review of
randomized controlled studies found no
conclusive evidence that this practice reduces
patient mortality or shortens the length of
hospital stay.22 The role of enteral immune-
enhancing nutrients (glutamine, arginine, omega-
3 fatty acids) on the outcome of patients with
severe thermal injury is controversial, and the
use of immune-enhancing formulas varies among
burn units.23, 24 Zinc, copper, selenium, and
vitamins C, E, and A play a role in wound
healing and reepithelialization.15 Supplemen-
tation of these micronutrients to the nutrition
regimen of patients with thermal injury is common
practice, although their exact requirements and
evidence supporting their use are unclear.25
Anabolic Hormone Therapy
Serum anabolic hormone concentrations are
decreased after severe thermal injury, which
negatively affects anabolism and wound healing.
Anabolic agents including recombinant human
growth hormone, recombinant human IGF-1,
insulin, testosterone, and oxandrolone have been
used in patients with severe thermal injury as
adjunct therapies to proper wound care, nutrition
support, and exercise programs during postburn
rehabilitation in order to promote anabolism,
protein synthesis, and wound healing; restore
body weight; and improve physical functionality.
However, these pharmacologic agents can be
associated with adverse events that limit their
clinical use.26
Recombinant Human Growth Hormone
Recombinant human growth hormone
increases cellular uptake of amino acids,
enhances protein synthesis, and improves wound
healing by binding to growth hormone receptors
or increasing IGF-1 release.26 In pediatric
patients with severe thermal injury, recombinant
human growth hormone improved wound
healing, bone mineralization, and growth.27
Recombinant human growth hormone use in
critically ill patients is limited because it may
cause hyperglycemia, hypertriglyceridemia, and
fluid retention, and increases metabolic rate.26, 27
Recombinant human growth hormone has been
safely used in critically ill patients with thermal
injury.27–29 However, two prospective, multi-
center, double-blind, randomized, placebo-
controlled studies of critically ill adult patients
without burn injury showed that administration
of subcutaneous recombinant human growth
hormone 0.1 mg/kg once/day for up to 21 days
was associated with increased morbidity and
mortality.30 Deaths were attributed to multiorgan
failure, septic shock, or uncontrolled infection.
Although patients with thermal injury were
excluded from the study, the study’s negative
results called into question the safety of growth
hormone use in critically ill patients.
Recombinant Human Insulin-Like Growth
Factor-1
The hormone IGF-1 (somatomedin-C) is a
polypeptide hormone that mediates the effects of
growth hormone. Recombinant human IGF-1
infusion in patients with severe thermal injury
increases protein synthesis and reduces hyper-
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metabolism. The effects of recombinant human
IGF-1 on wound healing are unclear. It is associated
with hypoglycemia and requires continuous
infusion that limits its clinical use.26 Intravenous
infusion of a recombinant compound of IGF-1
with its binding protein-3 (IGFBP-3) significantly
improved muscle protein synthesis in hyper-
catabolic patients with thermal injury; however,
the outcomes of IGF-1–IGFBP-3 infusion were
not superior to those observed with insulin or
testosterone alone, and the IGF-1–IGFBP-3 cost
outweighs its clinical benefits.1
Insulin
Insulin is a potent anabolic hormone that
increases protein synthesis and may improve
wound healing by increasing availability of
proteins for burn wounds.31 Because endogenous
insulin effects are hampered by insulin resistance,
exogenous insulin infusion is beneficial in
decreasing muscle protein loss by stimulating
protein synthesis and controlling hyperglycemia.32–34
Continuous insulin infusion suppresses hepatic
glucose production, enhances peripheral glucose
uptake, increases net protein synthesis, increases
lean body mass, and accelerates skin donor site
healing in patients with severe thermal injury.35–37
Maintaining normoglycemia (blood glucose
concentrations 80–110 mg/dl) in surgical critical
care adult patients with use of intensive contin-
uous-infusion insulin significantly decreased
patient morbidity and mortality.38 However,
intensive insulin therapy is associated with
hypoglycemia and requires continuous infusion
with around-the-clock blood glucose monitoring.
Severe hypoglycemia (blood glucose concentrations
< 40 mg/dl) is a risk factor for increased patient
morbidity and mortality.32, 38, 39
Testosterone
Testosterone binds to androgenic receptors and
increases cellular amino acid uptake and protein
synthesis. Testosterone may also improve wound
closure and reepithelialization, and stimulate
collagen synthesis and deposition in wounds.26
Testosterone enanthate 200 mg/week intramuscular
injection was associated with a 2-fold increase in
protein synthetic rate and significant reduction in
muscle protein breakdown.40 However, testosterone
use in patients with severe thermal injury has
been limited because of its androgenic effects and
potentially serious liver toxicity.41
Oxandrolone
Oxandrolone is a synthetic 17-methyl
derivative of testosterone but with a more favorable
pharmacologic profile. Oxandrolone has 10
times more anabolic effects and only 10% of the
adverse androgenic effects of testosterone. Because
of its improved safety profile and ease of oral
administration, oxandrolone is most commonly
used for its anabolic effects in patients with
severe thermal injury.40 In skeletal muscles,
oxandrolone binds to intracellular androgen
receptors. The androgen receptor–oxandrolone
complex then migrates to the cell nucleus where
it binds to DNA and stimulates protein synthesis
and anabolism. Oxandrolone also exhibits its
anabolic effects by countering the catabolic
effects of cortisol through competitive inhibition
of the glucocorticoid receptor.42 Protein kinetic
studies showed oxandrolone to increase intra-
cellular amino acid influx and utilization, and
improve the efficiency of skeletal muscle protein
synthesis. This effect may possibly be mediated
by an oxandrolone-induced increase of the
androgen receptor expression in skeletal muscles.
Oxandrolone, however, has no effect on intra-
cellular protein transport or protein break-down.
A DNA array analysis also showed that
oxandrolone alters the expression of 21 genes
and decreases the expression of transcription
factors and signaling molecules that are believed
to correlate with oxandrolone effects on amelio-
rating the inflammatory response of severe
thermal injury.43, 44 Further, oxandrolone effects
on wound repair may be mediated by stimulation
of procollagen messenger RNA expression in
fibroblasts, thereby increasing collagen synthesis
and deposition in the healing wound.45
Oxandrolone is well absorbed after oral
administration and is highly bound (94–97%) to
plasma proteins. In healthy volunteers, the
elimination half-life of oxandrolone in young
individuals is 10.4 hours but increases in the
elderly to 13.3 hours. Time to peak concentration,
peak plasma concentration, and bioavailability do
not differ with age.46 Unlike other anabolic
steroids, oxandrolone is not as extensively
metabolized by the liver. About 28% of the oral
oxandrolone dose is excreted unchanged in the
urine and about 3% is eliminated in the feces.47
Although no specific recommendations for
dosage adjustments have been published for
patients with decreased renal function, caution
should be used in patients with renal insuffi-
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ciency because oxandrolone can induce edema
and heart failure in patients with preexisting
renal, cardiac, or liver disease.46 Sodium and
water retention with exacerbation of hyper-
tension and deterioration of kidney function
were reported with oxandrolone 20 mg/day in
patients with severe renal insufficiency and
hypertension.48
Oxandrolone is labeled by the United States
Food and Drug Administration for use as adjunct
therapy to restore body weight after extensive
surgery, chronic infections, and severe trauma; to
offset protein catabolism associated with chronic
corticosteroid use; and to relieve osteoporotic
bone pain. Oxandrolone therapy can be associated
with serious adverse effects, but the frequency of
these adverse effects is unknown. Oxandrolone-
induced adverse effects may include hepatotoxi-
city (increased hepatic transaminase concen-
trations, hyperbilirubinemia, cholestatic jaundice,
hepatic failure), delayed bone growth and
premature closure of epiphyses in children,
sexual changes (clitoral enlargement, menstrual
irregularities), virilization (hirsutism, vocal cord
growth), genitourinary effects (priapism,
testicular atrophy, bladder irritation) mainly in
prepubertal male patients, hyperglycemia,
hyperlipidemia, electrolyte disturbances, and
central nervous system disturbances (depres-
sion, excitation, insomnia). The oxandrolone
package insert includes a black-box warning for
peliosis hepatitis, liver cell malignant tumors,
and dyslipidemia, as reported with androgens
and anabolic steroids. Contraindications to
oxandrolone include androgenic-sensitive
tumors, pregnancy, nephrosis, and hypercalcemia.46
In pediatric patients with severe thermal injury,
oxandrolone 0.1 mg/kg twice/day in the acute
postburn period improved serum visceral protein
concentrations, increased lean body mass
accretion, improved muscle strength, promoted
weight gain, and increased bone mineral content.
Also, during rehabilitation of pediatric patients
after thermal injury, oxandrolone 0.1 mg/kg/day
improved lean body mass, muscle strength, and
cardiopulmonary capacity in combination with
adequate nutrition and physical therapy.49–53
Oxandrolone 10 mg twice/day has been shown to
improve wound healing, restore lean body mass,
and promote weight gain in adults with severe
thermal injury.54–61
Clinical Studies of Oxandrolone
Table 1 summarizes the clinical studies of oxan-
drolone in adults with severe thermal injury,
including use of oxandrolone in the acute post-
burn period54–58 and in the rehabilitation period.59–61
Acute Postburn Period
A prospective, randomized, double-blind,
placebo-controlled study evaluated the effects of
oxandrolone in the acute postburn period in 20
adult patients with severe thermal injury.54
Beginning 2–3 days after thermal injury, patients
were randomly assigned to receive oxandrolone
10 mg twice/day (11 patients) or placebo (9
patients). Despite similar caloric and protein
intake between the two groups, oxandrolone-
treated patients had significantly less weight loss
(mean ± SD 3 ± 1.9 vs 8 ± 3 kg, p<0.05) and
nitrogen loss (4 ± 1.9 vs 13 ± 4 g/day, p<0.05)
over 3 weeks compared with placebo. Oxandrolone
caused significantly faster wound healing
compared with placebo (9 ± 2 vs 13 ± 3 days,
p<0.05). Mild asymptomatic elevation of liver
function tests (magnitude not reported) occurred
in 50% and 57% of patients in the oxandrolone
and control groups, respectively, but differences
were not statistically significant. Mean ± SD burn
unit length of stay for patients in the oxandrolone
and placebo groups was 29 ± 8 and 35 ± 9 days,
respectively. However, the small study sample
was insufficient to draw a valid comparison for
the length of stay.
A large multicenter, prospective, randomized,
double-blind, placebo-controlled study further
evaluated the effects of oxandrolone on the
length of stay in the acute postburn period in 81
adult patients.55 Patients were randomly assigned
to receive oxandrolone 10 mg twice/day (46
patients) or placebo (35 patients) beginning on
day 5 after thermal injury and continued until
hospital discharge. Study results showed
oxandrolone to be associated with a 27% shorter
length of hospital stay, which was significantly
shorter in oxandrolone-treated patients compared
with control (mean ± SD 31.6 ± 3.1 vs 43.3 ± 5.3
days, p=0.042). When patient mortality was
excluded, the length of stay remained signifi-
cantly shorter in the oxandrolone group compared
with placebo (32 ± 3.1 vs 45.3 ± 5.4 days,
p=0.035). Results were also consistent when
adjusted for percent TBSA burn and patient
mortality was excluded (mean ± SD 0.88 ± 0.07
vs 1.23 ± 0.15 days/%TBSA, p=0.015). Further,
oxandrolone-treated patients underwent
significantly fewer surgeries compared with
patients in the placebo group (2.2 ± 0.3 vs 4 ± 0.6
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surgeries/patient, p=0.015). After 7 weeks of
hospitalization, a significantly higher number of
asymptomatic increases in serum alanine
aminotransferase concentration (ALT > 100
mg/dl) was noted in the oxandrolone group
compared with placebo (21 vs 6, p=0.002). The
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Table 1. Clinical Studies of Oxandrolone in Adult Patients with Severe Thermal Injury
Duration of
Study Design Patient Population Nutrition Support Oxandrolone Therapya Primary Outcomes
Acute postburn
period
Prospective, Oxandrolone (n=11) Enteral, supplemental Mean ± SD of 33 ± 9 Net weight loss,
randomized, Placebo (n=9) parenteral p.r.n. days until transfer nitrogen loss, time
double-blind, 40–70% TBSA burn 32–34 kcal/kg to rehabilitation to wound healing,
placebo- Protein 1.6–1.7 g/kg metabolic rate,
controlled liver dysfunction,
(n=20)54 LOS
Prospective, Oxandrolone (n=46) Enteral or oral Started 5 days after LOS, hospital charges,
multicenter, Placebo (n=35) nutrition (amounts thermal injury and ventilator days,
randomized, 20–60% TBSA burn not reported) continued until discharge disposition
double-blind, hospital discharge
placebo-
controlled
(n=81)55
Prospective, Oxandrolone (n=11) Not reported Started within Time to wound
randomized, Control (n=11) 48 hrs of burn unit healing, weight loss,
controlled Mean ± SD % TBSA admissionb; duration complications
(n=22)56 burn: 33 ± 9% in not reported
patients with
thermal injury,
42 ± 15% in patients
with skin slough
disorders (TEN,
GVHD)
Prospective, Elderly (mean age 70 yrs) Not reported Started on admission Weight loss, wound
randomized, Oxandrolone (n=26) and continued until healing, nitrogen
controlled Control (n=24) discharge loss, LOS, infectious
(n=50)57 10–29% TBSA burn complications
Prospective, Adults with > 25% Enteral, supplemental Started 7–10 days Wound healing,
randomized, TBSA burn parenteral p.r.n. after thermal injury weight loss,
comparative Oxandrolone (n=16) Amino acids 2 g/kg/day and continued nitrogen loss
(n=60)58 RhGH (n=20) until discharge metabolic rate,
Control (n=24)c to rehabilitationb complications
Mean ± SD % TBSA
burn: 56 ± 15% in
both treatment
groups, 52 ± 14%
in control group
Postburn
rehabilitation
period
Prospective, Oxandrolone with Protein 2 g/kg/day in 3 wks Weight gain, muscle
randomized, high-protein diet (n=7) oxandrolone group strength
controlled High-protein diet (n=6) and in high-protein
(n=23)59 Lower protein diet diet group, 1.3–1.4
(n=10) g/kg/day in lower
30–50% TBSA burn protein diet group
30–35 kcal/kg/day
Prospective, Oxandrolone (n=23) 33–34 kcal/kg/day Started on admission Body weight, body
randomized, Control (n=22) Protein 1.4–1.6 to rehabilitation composition
controlled Mean ± SD % TBSA g/kg/day facility and continued
(n=45)60 burn: 40 ± 14% in until restoration of
oxandrolone group, 90% of body weightb
37 ± 15% in controls
OXANDROLONE THERAPY IN ADULTS WITH SEVERE THERMAL INJURY Miller and Btaiche
difference in the number of increased serum
aspartate aminotransferase concentrations (AST >
100 mg/dl) did not reach statistical significance
between the oxandrolone and placebo groups (11
vs 9, p=0.738). Because serum transaminase
concentrations were reported at the discretion of
investigators, a valid conclusion of oxandrolone
effects on liver function tests cannot be drawn.
The authors attribute the lack of generated cost
savings despite decreased length of stay to
possible inadequate study power to test for costs,
or to the relatively higher costs earlier in the
course of patient hospital stay, with hospital
charges possibly linked to diagnosis-related
groups and billing codes that do not account for
the length of stay in the charges. The study was
halted with approximately half of projected
subjects enrolled because interim analysis
showed significant difference in favor of
oxandrolone compared with placebo.
Corticosteroids increase catabolism, blunt the
inflammatory phase of wound healing, and
reduce collagen deposition, which further impair
wound healing.62, 63 A prospective, randomized,
controlled study evaluated the effects of
oxandrolone on wound healing in 22 adult
patients with severe thermal injury (12 patients)
or skin slough disorders (toxic epidermal
necrolysis in seven patients, graft-versus-host
disease in three) who were receiving high-dose
corticosteroids for treatment of diseases
necessitating steroid therapy (e.g., collagen
vascular disease, solid-organ transplantation,
bone marrow transplantation, asthma).56 At
baseline, patients with thermal injury were
receiving a mean ± SD hydrocortisone dose of
150 ± 50 mg/day, and those with skin slough
disorders 190 ± 75 mg/day. Patients were
randomly assigned to receive standard care, or
standard care with oxandrolone 20 mg/day
starting within 48 hours of admission to the burn
unit. Patients treated with corticosteroids were
also compared with a similar group of non–
steroid-treated patients with thermal injury (15
patients) or toxic epidermal necrolysis (10
patients) who received the same standard care
during the same time period. Patients treated
with hydrocortisone and who received oxandrolone
had significantly faster donor site wound healing
(mean ± SD 13 ± 3 vs 20 ± 4 days, p<0.05) and
43% less weight loss (4 ± 2 vs 7 ± 3 kg, p<0.05)
compared with patients receiving standard care
alone (control group). Similarly, patients with
skin slough disorders treated with hydrocortisone
and who received oxandrolone had significantly
faster wound reepithelialization (mean ± SD 17 ±
4 vs 25 ± 6 days, p<0.05) and 50% less weight
loss (4 ± 2 vs 8 ± 3 kg, p<0.05) compared with
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Table 1. (continued)
Results
Oxandrolone significantly decreased weight loss, nitrogen
loss, and wound healing time; no significant differences
in metabolic rate or hepatic effects; LOS could not be
compared
Compared with placebo, oxandrolone decreased LOS
(mean ± SD 31.6 ± 3.1 vs 43.3 ± 5.3 days, p=0.042) and
decreased LOS adjusted for mortality and for % TBSA burn;
there were fewer surgeries/patient in oxandrolone group;
the oxandrolone group had significantly more occurrences
of ALT concentration elevations; no significant differences
in ventilator days, discharge disposition, or hospital charges
Compared with control, oxandrolone, decreased time to
wound healing (mean ± SD 13 ± 3 vs 20 ± 4 days, p<0.05);
oxandrolone reduced weight loss; no significant difference
in complications
Oxandrolone reduced weight loss in the 10–19% and
20–29% TBSA burn subgroups; it decreased time to wound
healing, nitrogen loss, and LOS adjusted for % TBSA burn;
no significant difference in incidence of pneumonia
Compared with control, oxandrolone and RhGH decreased
time to wound healing (mean ± SD 14 ± 2 vs 10 ± 2 and
10 ± 3 days, p<0.05), nitrogen loss (11 ± 3.2 vs 3 ± 1.5
and 4 ± 2.4 g/day, p<0.05), and weight loss; RhGH
increased metabolic rate vs control (mean ± SD 72 ± 11 vs
50 ± 12%, p<0.05) and caused hyperglycemia; no
significant differences between oxandrolone and RhGH
groups for skin donor site healing time, weight loss, or
nitrogen loss; no significant difference in percentage of
patients who had increased liver function test results
Oxandrolone plus high-protein diet caused more significant
absolute weekly weight gain vs high-protein diet alone
(mean 1.7 vs 1.1 kg in week 1, 1.8 vs 1.1 kg in week 2,
and 2.1 vs 1.1 kg in week 3, p<0.05); high-protein diet
alone caused more significant weekly weight gain vs lower
protein diet alone (mean 1.1 vs 0.5 kg in week 1, 1.1 vs
0.5 kg in week 2, and 1.1 vs 0.6 kg in week 3, p<0.05)
Oxandrolone increased muscle strength; body weight at
weeks 1, 2, 3, and 4; and lean body mass at discharge and
at 6 mo after discharge; no complications reported
PHARMACOTHERAPY Volume 29, Number 2, 2009
the control group. Patients who received
standard care alone but were treated with
corticosteroids had longer donor site wound
healing time compared with patients who did not
receive corticosteroids (mean ± SD 20 ± 4 vs 12 ±
3 days for burned patients, 25 ± 6 vs 18 ± 4 days
for patients with skin slough disorders); however,
these differences were not statistically significant.
Mild, transient elevations of serum AST and ALT
concentrations were reported in five patients in
the oxandrolone group and in seven patients in
the standard-care group. Increases in serum
transaminase concentrations were deemed related
to stress effects on the liver rather than to
oxandrolone. No hirsutism was reported in the
11 women who received oxandrolone for 3–4
weeks. Oxandrolone had no effect on infection
rates. Although oxandrolone enhanced wound
healing even during corticosteroid therapy, it is
unclear whether this effect was due to counter-
acting the catabolic and antiinflammatory effects
of corticosteroids. It is counterproductive if
oxandrolone blunts the antiinflammatory effects
of corticosteroids.
Elderly patients with severe thermal injury are
at increased risk for morbidity and mortality due
to decreased immune function, higher
susceptibility to infections, and high risk for
cardiopulmonary failure.64, 65 With older age,
decreased physical function, lean body mass, and
endogenous anabolic hormone synthesis delay
wound healing and recovery in elderly patients
with severe thermal injury.66 Fifty elderly
patients (mean age 70 yrs) with 10–29% TBSA
burn were randomly assigned on admission to
the burn unit to receive oxandrolone 10 mg
twice/day plus standard thermal injury care or
standard care alone (control group).57 Patients
were stratified by percent TBSA burn subgroups:
10–19% and 20–29%. The oxandrolone dosage
was adjusted to once/day in patients with
creatinine clearances that were less than 25% of
normal for age. Oxandrolone was continued
until discharge or transfer to a rehabilitation
facility. Oxandrolone use was associated with
significantly less body weight loss (as a
percentage of total weight) compared with the
control group in both the 10–19% TBSA burn
subgroup (mean ± SD 4 ± 2% vs 9 ± 2%, p<0.05)
and the 20–29% TBSA burn subgroup (5 ± 3% vs
9 ± 2%, p<0.05). Time to donor site wound
healing was significantly shorter in patients
treated with oxandrolone compared with the
control group in both the 10–19% TBSA burn
subgroup (12 ± 4 vs 16 ± 5 days, p<0.05) and the
20–29% TBSA burn subgroup (12 ± 5 vs 17 ± 5
days, p<0.05). At all time periods, patients in the
oxandrolone group had significantly less net
nitrogen loss than the control group (p<0.05).
Length of burn unit stay adjusted for percent
TBSA burn was also significantly shorter in the
oxandrolone group compared with control
(p<0.05) and also compared with predicted
national average length of stay for age and degree
of thermal injury (p<0.05). Skin graft loss
(defined as > 15% loss) as a surrogate marker of
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Table 1. Clinical Studies of Oxandrolone in Adult Patients with Severe Thermal Injury (continued)
Duration of
Study Design Patient Population Nutrition Support Oxandrolone Therapya Primary Outcomes
Postburn
rehabilitation
period
(continued)
Prospective, Oxandrolone (n=21) 18–40-yr-old group: 4 wks or until recovery Weight gain, lean
randomized, Control (n=19) 31 ± 5 kcal/kg/day of preburn weight body mass gain,
controlled, Mean ± SD % TBSA Protein 1.6 g/kg/day functional
parallel-group burn by age: ≥ 55-yr-old group: independence
(n=40)61 47 ± 10% (18–40 yrs) 30 ± 6 kcal/kg/day
vs 36 ± 5% (≥ 55 yrs), Protein 1.5 g/kg/day
p<0.05
TBSA = total body surface area; LOS = length of stay; ALT = alanine aminotransferase; TEN = toxic epidermal necrolysis; GVHD = graft-versus-
host disease; RhGH = recombinant human growth hormone.
aUnless otherwise indicated, oxandrolone daily dose was 20 mg, administered as 10 mg twice/day.
bThe oxandrolone dosage was reported at 20 mg/day, but whether it was given once/day or divided into two daily doses was not specified.
cPatients with severe thermal injury (> 50% TBSA burn, or > 25% TBSA burn with impaired would healing or comorbidities) who were not
eligible for oxandrolone therapy.
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infection and wound healing was significantly
less in the oxandrolone group compared with
that in the control group. Pneumonia was
diagnosed in 20% of the oxandrolone-treated
patients and 30% of patients in the control group.
Transient asymptomatic 2-fold increases in serum
AST and ALT concentrations from baseline
occurred in 20% of patients in the oxandrolone
group (no drug discontinuation needed) and 25%
of patients in the control group. To our
knowledge, this is the first study of patients with
severe thermal injury to reduce the oxandrolone
dosage by 50% from 10 mg twice/day to 10
mg/day in patients with decreased renal function.
However, the total daily dose of oxandrolone
administered to patients with normal renal
function was twice the maximum dosage of 5 mg
twice/day recommended for geriatric patients.46
Oxandrolone versus Recombinant Human Growth
Hormone
A prospective, randomized, nonblinded study
compared the anabolic effects of oxandrolone
versus recombinant human growth hormone in
the acute postburn period in 60 adult patients
with severe thermal injury.58 Patients were
randomly assigned to receive oxandrolone 20
mg/day (16 patients) or intramuscular injection
of human growth hormone 0.1 mg/kg/day (20
patients) beginning 7–10 days after thermal
injury and having reached at least 85% of daily
caloric and protein intake. Treatment continued
until wound healing and recovery was sufficient
to allow transfer to rehabilitation. Data were also
compared with that of a control group of 24
patients with severe thermal injury in the burn
unit who did not meet the study inclusion
criteria for oxandrolone therapy. At baseline,
patients in the oxandrolone and human growth
hormone groups had significantly greater percent
TBSA burn and percent TBSA full-thickness
thermal injury compared with the control group.
Among patients with at least 25% TBSA burn
with comorbid conditions, significantly more
patients who received oxandrolone (seven
patients) and human growth hormone (eight
patients) had adult-onset diabetes mellitus
compared with eight patients in the control
group (72% and 80% vs 15%, p<0.05). Study
results showed that patients treated with
oxandrolone and human growth hormone had
significantly faster donor site healing than the
control group (mean ± SD 10 ± 2 and 10 ± 3 vs
14 ± 2 days, p<0.05). Further, patients in the
oxandrolone and human growth hormone groups
had significantly less net weight loss during
therapy than patients in the control group (mean
± SD 3 ± 2 and 4 ± 2 vs 8 ± 3 kg, p<0.05). Net
daily nitrogen loss was significantly lower in the
oxandrolone and human growth hormone groups
compared with control. Patients treated with
human growth hormone had a significant percent
increase in their metabolic rate compared with
control. All patients treated with human growth
hormone developed hyperglycemia (serum
glucose concentrations > 225 mg/dl) compared
with 52% of patients in the oxandrolone group
and 55% in the control group (p<0.05). To
maintain serum glucose concentrations below
225 mg/dl, greater than 60% of patients treated
with human growth hormone required insulin
therapy, compared with 28% and 25% of patients
in the oxandrolone and control groups,
respectively. A significantly higher percentage of
patients treated with human growth hormone
had underlying diabetes compared with the
control group (80% vs 18%, p<0.05), which may
have further exacerbated hyperglycemia in the
human growth hormone group. The percentages
of patients who developed mild asymptomatic
increases in serum AST, ALT, or alkaline
phosphatase concentrations (increase by not
more than 1.5 times normal) were similar in the
oxandrolone, human growth hormone, and
control groups. No hirsutism was reported in
any of the groups. The length of burn unit stay
was not compared because of significant baseline
differences in thermal injury severity and
comorbidities between the treatment and control
groups. Although oxandrolone and human
growth hormone showed similar beneficial effects
on wound healing and nitrogen retention in adult
patients with severe thermal injury, human
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Table 1. (continued)
Results
Oxandrolone increased mean weekly weight in younger and
older patients by 1.7 and 1.6 kg, compared with 0.7 and
0.4 kg in the control group, respectively (p<0.05); the drug
increased lean body mass as percentage of total weight
gain in younger (mean ± SD 79 ± 4% vs 59 ± 9%, p<0.05)
and older groups (mean ± SD 76 ± 5% vs 51 ± 6%, p<0.05)
vs control; it increased functional independence at weeks 3
and 4 in older patients; it also decreased LOS in both age
groups
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growth hormone was associated with a 2-fold
increase in occurrence of hyperglycemia.
Although historically hyperglycemia in critically
ill patients was loosely defined as serum glucose
concentrations exceeding 200 mg/dl, this high
threshold is no longer acceptable. Intensive
insulin therapy is a standard of practice to
control hyperglycemia in critically ill patients
and has been shown to decrease patient
morbidity and mortality.38, 67 A study limitation is
the baseline mismatch in percent TBSA burn
between the treatment and control groups, and
the control group supposedly consisted of
excluded patients who did not meet the criteria
for oxandrolone therapy.
Rehabilitation Period
The effects of oxandrolone on weight gain and
muscle function were evaluated in a prospective,
randomized, controlled study during rehabili-
tation of adult patients after thermal injury.59
The treatment group (seven patients) received
oxandrolone 10 mg twice/day with a high-protein
2-g/kg/day diet and was compared with two
groups: an active control group of six patients
with thermal injury who received a similar high-
protein 2-g/kg/day diet but no study drug, and a
retrospective group of 10 patients with severe
thermal injury who consumed a lower protein
1.3–1.4-g/kg/day diet but no study drug. Patients
included in the study were anticipated to require
at least 3 weeks of rehabilitation, and they
reached the recovery period within 4–6 weeks
after thermal injury. Patients in all groups lost
about 9 kg (12% of usual body weight) during
their acute postburn period. Study results
showed that during the recovery phase, overall
average weight gain at the end of 3 weeks was
significantly higher in the oxandrolone plus
high-protein diet group compared with the high-
protein and lower protein diets alone groups
(mean ± SD 6.6 ± 1.1 vs 3.4 ± 0.7 and 2 ± 0.3 kg,
p<0.05). Muscle strength as assessed by physical
therapy index (using cumulative endurance and
strength exercise criteria ranking from lowest = 0
to highest = 10) was significantly higher at 3
weeks in the oxandrolone plus high-protein diet
group compared with the high-protein diet and
lower protein diet alone groups (8.8 ± 0.5 vs 7 ±
0.8 vs 4.1 ± 0.5, p<0.05); the difference in muscle
strength between the high-protein diet alone and
lower protein diet groups was also significant
(p<0.05). An asymptomatic transient increase of
serum alkaline phosphatase concentration
(magnitude not reported) was reported in one
patient in each of the oxandrolone and higher
protein diet groups, but resolved spontaneously
without oxandrolone discontinuation. No
hirsutism, acne, or behavioral changes were
reported. This study stressed the importance of
high-protein intake at 2 g/kg/day on weight gain
and muscle strength throughout rehabilitation of
adults with severe thermal injury. A 1.7-fold
increase in body weight gain during the 3-week
rehabilitation program could be attributed to
increasing protein intake alone from 1.4 to 2
g/kg/day. Further, a 2-fold body weight gain
resulted from the addition of oxandrolone to the
high-protein diet along with exercise. This study,
however, did not address the effects of
oxandrolone with high-protein intake and
exercise on lean body mass changes.
The same investigators further evaluated the
long-term effects of oxandrolone during and after
rehabilitation of adults with severe thermal
injury.60 Forty-five adults with severe thermal
injury who were anticipated to have at least 3
weeks of postburn rehabilitation were included
in a prospective, randomized, controlled study.
On admission to the rehabilitation facility,
patients were randomly assigned to receive
oxandrolone 20 mg/day in addition to adequate
nutrition and exercise (23 patients) or to the
control group where they received only adequate
nutrition and exercise (22 patients). Oxandrolone
was continued until restoration of at least 90% of
lost weight. Body weight and body composition
(bioelectric impedance analysis) were recorded at
discharge from the rehabilitation facility, 6
months after discharge, and 6 months after
oxandrolone discontinuation. Weight loss as a
percentage of baseline body weight during the
acute postburn period was similar in the
oxandrolone and control groups (mean ± SD 10 ±
2% vs 9 ± 2%, p>0.05). Absolute weight gain was
significantly higher in oxandrolone-treated
patients compared with patients in the control
group (1.8 vs 0.6 kg, 1.5 vs 0.7 kg, 1.5 vs. 0.7 kg,
and 1.5 vs. 0.7 kg during weeks 1, 2, 3, and 4,
respectively, p<0.05). During rehabilitation,
oxandrolone-treated patients regained body
weight and lean body mass 2–3 times faster than
patients receiving nutrition and exercise alone.
At time of discharge from the rehabilitation
facility, patients treated with oxandrolone had
significantly more lean body mass (as percentage
of total body weight) compared with patients
who received nutrition and exercise alone (mean
± SD 76 ± 4% vs 71 ± 3%, p<0.05). The
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difference was also sustained at 6 months after
discharge. Of interest, less additional body
weight gain from time of discharge to 6 months
after discharge was reported in oxandrolone-
treated patients compared with the control group,
although the difference was not statistically
significant (mean ± SD 2.8 ± 1 vs 4.1 ± 1.2 kg,
p>0.05). Study results provide additional data of
oxandrolone benefits on restoring lean body mass
during rehabilitation and the rate of lean body
mass regain extends for 6 months after
oxandrolone discontinuation. This was achieved
in combination with a rehabilitation exercise
program and adequate nutrition.
A study of similar design by the same
investigators randomly assigned 40 adult patients
with severe thermal injury to receive oxandrolone
10 mg twice/day in addition to nutrition and
exercise or nutrition and exercise alone during
rehabilitation.61 Patients were stratified by age:
the younger group included 25 patients aged
18–40 years (mean ± SD 34 ± 5 yrs) and the older
group included 15 patients aged 55 years or older
(60 ± 5 yrs). Patients with prostate mass or
history of prostate cancer were excluded from the
study. Oxandrolone was started on admission to
the rehabilitation facility and continued for 4
weeks or until patients recovered their preburn
body weight. At baseline, younger patients had
significantly larger percent TBSA burn, shorter
burn unit stay, and shorter ventilator-dependence
time, compared with older patients. Absolute
weekly weight gain was significantly higher in
younger patients treated with oxandrolone by
weeks 2, 3, and 4 compared with patients in the
nutrition and exercise group alone (1.7 vs 0.7 kg,
1.8 vs 0.7 kg, and 1.8 vs 0.8 kg, respectively,
p<0.05). Similarly, absolute weekly weight gain
was significantly higher in older patients treated
with oxandrolone compared with the nutrition
and exercise group alone by weeks 1, 2, 3, and 4
(1.1 vs 0.3 kg, 1.6 vs 0.5 kg, 1.5 vs 0.5 kg, and
1.7 vs 0.6 kg, respectively, p<0.05). Lean body
mass accretion (using bioelectric impedance
analysis) at week 4 of oxandrolone therapy was
significantly higher in both younger and older
groups compared with respective controls (mean
± SD 7 ± 2.2 vs 3 ± 1.2 kg and 6 ± 1.9 vs 2 ± 0.9
kg, respectively, p<0.05). Younger and older
patients treated with oxandrolone also had lower
fat mass as percentage of total body weight
compared with controls, but these differences
were not statistically significant. Measurement of
musculoskeletal function was assessed by using
the functional independence measurement (FIM)
scoring system that measures muscle endurance,
strength, and function. On admission to the
rehabilitation facility, all patients had significant
impairment of their functional capacity with an
absolute average FIM score of about 77 for the
younger group (normal range 115–120) and 70
for the older group (normal range 105–110).
Younger patients treated with oxandrolone had
higher FIM scores by weeks 2, 3, and 4 compared
with patients in the nutrition and exercise group
alone (mean ± SD 95 ± 8 vs 85 ± 7, 105 ± 8 vs 88
± 6, and 107 ± 9 vs 90 ± 5, respectively, p<0.05).
Older patients treated with oxandrolone achieved
higher FIM scores only at weeks 3 and 4
compared with patients in the nutrition and
exercise group alone (92 ± 5 vs 84 ± 8 and 96 ± 6
vs 86 ± 7, respectively, p<0.05). About 30%
shorter length of rehabilitation time was reported
in all patients treated with oxandrolone. Both
younger and older patients treated with oxan-
drolone had significantly shorter rehabilitation
stay compared with their respective controls (23
± 6 vs 31 ± 5 days and 34 ± 5 vs 42 ± 5 days,
respectively, p<0.05). No patient treated with
oxandrolone developed hirsutism or behavioral
changes. Three patients treated with oxandrolone
had a transient increase in alkaline phosphatase
concentration not exceeding a 50% increase
above normal, which resolved spontaneously
without oxandrolone discontinuation. This was
the only study, to our knowledge, that showed
oxandrolone to significantly shorten the length of
inpatient rehabilitation time in adults with severe
thermal injury. The benefits of oxandrolone, in
combination with an adequate nutrition and
exercise program, were significant in increasing
the rate of lean body mass restoration, promoting
rapid regain of body weight, and rapidly restoring
functional capacity in the rehabilitation of young
and elderly patients with severe thermal injury.
Further, older patients had significantly longer
duration of dependence on mechanical ventilation
and longer burn unit stay compared with the
younger group. The study did not compare the
outcomes of the younger with that of the older
patient groups. A study limitation was that older
patients received similar amounts of calories
(average 35 kcal/kg/day) to that of younger
patients, which would have provided relatively
higher daily calories than required to older
patients considering their lower body cell mass
with aging. Excessive calorie intake from carbo-
hydrates and fat would result in a significant
increase in body fat weight rather than body cell
mass weight.
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Summary of Efficacy
Adjunct oxandrolone 10 mg twice/day in adult
patients with severe thermal injury improves
burn wound healing, restores lean body mass,
promotes weight gain, and may shorten the
length of hospital stay. During postburn
rehabilitation, oxandrolone in combination with
proper nutrition and exercise increased lean body
mass accretion, promoted body weight gain,
increased muscle strength, restored patient
functional capacity, and shortened the length of
rehabilitation. Although oxandrolone effects on
serum visceral protein concentrations and bone
mineralization have not been evaluated in adult
patients with severe thermal injury, studies in
pediatric patients with severe thermal injury
showed oxandrolone to improve serum albumin,
prealbumin, and retinol-binding protein
concentrations and to increase bone mineral
content.49–52
Safety
In the above-discussed clinical studies of
patients with severe thermal injury, oxandrolone
was well tolerated. Mild asymptomatic and
reversible increases in serum AST, ALT, and
alkaline phosphatase concentrations were
reported. No hirsutism, behavioral changes, or
virilization were reported. Studies in pediatric
patients with severe thermal injury reported
clitoromegaly and clitoral hood redundancy that
were reversible after oxandrolone discontinu-
ation.68–70 Because the longest duration of
continuous oxandrolone therapy in the clinical
studies of adult patients with thermal injury was
about 4 weeks, the safety of extended oxandrolone
therapy in this patient population is unknown.
Studies in pediatric patients with severe thermal
injury show that oxandrolone is well tolerated for
up to 1 year of therapy.50
In a retrospective review of 14 adult patients in
a burn intensive care unit who were treated with
oxandrolone 5 or 10 mg twice/day, no significant
difference was noted in hepatic dysfunction
(assessed by any increase above baseline of serum
AST, ALT, total and direct bilirubin, and alkaline
phosphatase concentrations) in patients treated
with oxandrolone compared with a historical
control group of patients who did not receive
oxandrolone.71 However, study limitations
included the inconsistency in measuring and
documenting liver function tests, retrospective
design, and small sample size. Serum liver
transaminase concentrations should be closely
monitored during oxandrolone therapy. Increases
in serum transaminase concentrations could
indicate oxandrolone-induced liver toxicity.
Serum alkaline phosphatase concentrations may
not be specific markers of liver toxicity because
bone resorption with elevated serum alkaline
phosphatase concentrations occur in patients
with severe thermal injury.68 If serum alkaline
phosphatase concentrations become elevated,
specific serum alkaline phosphatase liver and
bone activities should be measured. Oxandrolone
should be discontinued whenever significant or
persistent elevation of serum liver function tests
occurs, or when potentially serious adverse
effects are suspected. Although oxandrolone
does not undergo extensive liver metabolism,
oxandrolone should be avoided in patients with
hepatic insufficiency because of its risk of liver
toxicity. Because the elimination half-life of
oxandrolone is longer in the elderly who also
have greater susceptibility to oxandrolone-
induced liver toxicity and fluid retention, a lower
oxandrolone dose of 5 mg twice/day is
recommended in the elderly population.46
Concerns have been raised about the possible
adverse effects of oxandrolone on prolonging the
duration of mechanical ventilation in critically ill
surgical patients. In a study of critically ill
ventilator-dependent trauma and surgical patients,
oxandrolone 10 mg twice/day significantly
prolonged the duration of mechanical ventilation
and was associated with a higher rate of
reintubation.72 The investigators hypothesized
that longer ventilator dependence could possibly
be related to oxandrolone increasing collagen
deposition in the lungs during the later stage of
the acute respiratory distress syndrome, causing
lung fibrosis and leading to delayed pulmonary
recovery. Although this study did not include
patients with thermal injury, close monitoring of
patients’ respiratory function and ventilator
dependence is required in critically ill patients
with thermal injury who receive oxandrolone and
who require prolonged ventilator support.
Because anabolic steroids stimulate androgen-
sensitive tissues and increase the risk of prostate
hypertrophy and prostate carcinoma, patients
with severe thermal injury who have a history of
malignancies or elevated serum prostate-specific
antigen concentrations should not receive
oxandrolone.
Cost
The 2008 average wholesale price of oxandrolone
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2.5-mg tablets ranged from $5.25–7.14/tablet,
and for the 10-mg tablets from $17.80–24.20/
tablet.73 Thus, use of oxandrolone 10-mg tablets
at doses of 10 mg twice/day results in a daily
drug cost of $36–48.
Conclusion
Oxandrolone 10 mg twice/day improves
wound healing, restores lean body mass, and
promotes body weight gain in adult patients with
severe thermal injury. During the postburn
rehabilitation period, oxandrolone therapy in
conjunction with adequate nutrition and an
exercise program improves lean body mass,
increases muscle strength, and restores body
weight. Close patient monitoring during
oxandrolone therapy, especially for liver function,
is recommended. Although data on the efficacy
and safety of oxandrolone in adult patients with
severe thermal injury are derived from prospective,
randomized, controlled studies, limitations are
that they mostly originated from a single study
center, had relatively small numbers of subjects
enrolled, were usually nonblinded, and did not
describe institutional review board approval or
patient consent. Well-designed, large, multicenter,
prospective, randomized studies are needed to
better define the optimal oxandrolone dosage,
and confirm the safety and efficacy in adult
patients with severe thermal injury.
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